Skip to main content

Grafa News and Videos — Page 1592

Latest

Grafa

Eli Lilly secures FDA approval for Foundayo, first non-peptide weight loss pill

Eli Lilly and Company (NYSE:LLY) announced on Wednesday, April 1, 2026, that the U.S. Food and Drug Administration (FDA) has approved Foundayo™ (orforglipron) for chronic weight management in adults with obesity, or those who are overweight with at least one weight-related condition.

Read more: Eli Lilly secures FDA approval for Foundayo, first non-peptide weight loss pill

GET YOUR GRAFA EDGE NOW

We'll switch on a 30-day Edge trial as a welcome gift